Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Equillium, Inc. stock logo
EQ
Equillium
$0.35
-7.9%
$0.44
$0.34
$1.53
$13.42M2.06357,539 shs149,349 shs
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$0.55
-1.8%
$0.57
$0.36
$6.30
$3.21M0.42144,832 shs52,886 shs
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$0.29
+5.5%
$0.18
$0.10
$1.75
$13.04M0.841.57 million shs74,823 shs
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.37
+4.3%
$0.33
$0.22
$5.22
$15.16M-0.472.80 million shs827,365 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Equillium, Inc. stock logo
EQ
Equillium
-7.85%-12.60%-21.36%-54.69%-74.92%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
-1.78%-2.56%-5.56%-8.68%-90.30%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
+5.45%+11.54%+107.00%-45.64%-82.32%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
+4.29%+18.89%+7.48%-18.67%-92.91%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Equillium, Inc. stock logo
EQ
Equillium
2.9513 of 5 stars
3.25.00.00.02.91.70.6
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
2.0113 of 5 stars
3.50.00.00.00.61.71.3
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
2.3743 of 5 stars
0.05.00.00.03.61.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Equillium, Inc. stock logo
EQ
Equillium
2.33
Hold$3.00766.80% Upside
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
3.00
Buy$0.8553.85% Upside
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00
N/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NBY, EQ, NKGN, and PRPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/28/2025
Equillium, Inc. stock logo
EQ
Equillium
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
3/28/2025
Equillium, Inc. stock logo
EQ
Equillium
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$3.00 ➝ $1.00
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Equillium, Inc. stock logo
EQ
Equillium
$30.41M0.41N/AN/A$0.64 per share0.54
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$9.78M0.33N/AN/A$4.25 per share0.13
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$80K162.94N/AN/A($2.68) per share-0.11
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$5.85M2.59N/AN/A$2.74 per share0.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Equillium, Inc. stock logo
EQ
Equillium
-$13.34M-$0.39N/AN/AN/A-10.05%-20.68%-10.77%8/6/2025 (Estimated)
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
-$9.64M-$53.72N/AN/AN/A-102.72%-7,293.78%-158.41%N/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
-$82.94M-$2.45N/AN/AN/AN/A-479.36%N/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$16.78M-$1.26N/AN/AN/A-217.64%-62.92%-30.22%8/13/2025 (Estimated)

Latest NBY, EQ, NKGN, and PRPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2025Q1 2025
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$0.18-$0.12+$0.06$0.12$2.45 million$1.43 million
3/27/2025Q4 2024
Equillium, Inc. stock logo
EQ
Equillium
-$0.22-$0.16+$0.06-$0.16N/A$4.39 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Equillium, Inc. stock logo
EQ
Equillium
N/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Equillium, Inc. stock logo
EQ
Equillium
N/A
3.04
3.04
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A
1.15
0.91
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A
0.02
0.02
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.48
1.47
1.33

Institutional Ownership

CompanyInstitutional Ownership
Equillium, Inc. stock logo
EQ
Equillium
27.05%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
23.25%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
76.17%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.45%

Insider Ownership

CompanyInsider Ownership
Equillium, Inc. stock logo
EQ
Equillium
31.60%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
0.10%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
10.36%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
20.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Equillium, Inc. stock logo
EQ
Equillium
4035.72 million24.70 millionNot Optionable
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
305.82 million4.88 millionNot Optionable
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A44.95 million40.29 millionNot Optionable
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
13041.54 million18.93 millionOptionable

Recent News About These Companies

ProPhase Labs's Earnings Outlook
ProPhase Labs Delays Form 10-Q Filing
ProPhase Labs reports FY24 EPS ($2.61) vs (98c) last year
ProPhase Labs FY 2024 Earnings Preview

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Equillium stock logo

Equillium NASDAQ:EQ

$0.35 -0.03 (-7.85%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$0.37 +0.02 (+6.91%)
As of 05/29/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

NovaBay Pharmaceuticals stock logo

NovaBay Pharmaceuticals NYSE:NBY

$0.55 -0.01 (-1.78%)
As of 05/29/2025 03:56 PM Eastern

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

NKGen Biotech stock logo

NKGen Biotech NYSE:NKGN

$0.29 +0.02 (+5.45%)
As of 05/29/2025 03:46 PM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

ProPhase Labs stock logo

ProPhase Labs NASDAQ:PRPH

$0.36 +0.02 (+4.29%)
Closing price 05/29/2025 03:58 PM Eastern
Extended Trading
$0.36 -0.01 (-2.74%)
As of 05/29/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.